Suppr超能文献

早期预测乳腺癌新辅助治疗的病理反应:MRI 准确性的系统评价。

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.

机构信息

Screening and Test Evaluation Program (STEP), Sydney School of Public Health, A27, Edward Ford Building, The University of Sydney, NSW 2006, Australia.

出版信息

Breast. 2012 Oct;21(5):669-77. doi: 10.1016/j.breast.2012.07.006. Epub 2012 Aug 3.

Abstract

Magnetic resonance imaging (MRI) has been proposed to have a role in predicting final pathologic response when undertaken early during neoadjuvant chemotherapy (NAC) in breast cancer. This paper examines the evidence for MRI's accuracy in early response prediction. A systematic literature search (to February 2011) was performed to identify studies reporting the accuracy of MRI during NAC in predicting pathologic response, including searches of MEDLINE, PREMEDLINE, EMBASE, and Cochrane databases. 13 studies were eligible (total 605 subjects, range 16-188). Dynamic contrast-enhanced (DCE) MRI was typically performed after 1-2 cycles of anthracycline-based or anthracycline/taxane-based NAC, and compared to a pre-NAC baseline scan. MRI parameters measured included changes in uni- or bidimensional tumour size, three-dimensional volume, quantitative dynamic contrast measurements (volume transfer constant [Ktrans], exchange rate constant [k(ep)], early contrast uptake [ECU]), and descriptive patterns of tumour reduction. Thresholds for identifying response varied across studies. Definitions of response included pathologic complete response (pCR), near-pCR, and residual tumour with evidence of NAC effect (range of response 0-58%). Heterogeneity across MRI parameters and the outcome definition precluded statistical meta-analysis. Based on descriptive presentation of the data, sensitivity/specificity pairs for prediction of pathologic response were highest in studies measuring reductions in Ktrans (near-pCR), ECU (pCR, but not near-pCR) and tumour volume (pCR or near-pCR), at high thresholds (typically >50%); lower sensitivity/specificity pairs were evident in studies measuring reductions in uni- or bidimensional tumour size. However, limitations in study methodology and data reporting preclude definitive conclusions. Methods proposed to address these limitations include: statistical comparison between MRI parameters, and MRI vs other tests (particularly ultrasound and clinical examination); standardising MRI thresholds and pCR definitions; and reporting changes in NAC based on test results. Further studies adopting these methods are warranted.

摘要

磁共振成像(MRI)已被提议在乳腺癌新辅助化疗(NAC)早期用于预测最终病理反应。本文研究了 MRI 在早期反应预测中的准确性的证据。系统文献检索(至 2011 年 2 月)用于识别报告在 NAC 期间 MRI 预测病理反应准确性的研究,包括对 MEDLINE、PREMEDLINE、EMBASE 和 Cochrane 数据库的检索。有 13 项研究符合条件(共 605 例患者,范围 16-188 例)。动态对比增强(DCE)MRI 通常在 1-2 个周期的蒽环类或蒽环类/紫杉类 NAC 后进行,并与 NAC 前基线扫描进行比较。测量的 MRI 参数包括单维或二维肿瘤大小、三维体积、定量动态对比测量(体积转移常数[Ktrans]、交换率常数[k(ep)]、早期对比摄取[ECU])和肿瘤缩小的描述性模式。用于识别反应的阈值在不同的研究中有所不同。反应的定义包括病理完全缓解(pCR)、接近 pCR 和有 NAC 效果的残留肿瘤(反应范围 0-58%)。由于 MRI 参数和结局定义的异质性,排除了统计荟萃分析。基于数据的描述性呈现,在测量 Ktrans(接近 pCR)、ECU(pCR,但非接近 pCR)和肿瘤体积(pCR 或接近 pCR)减少的研究中,预测病理反应的灵敏度/特异性对最高,在高阈值(通常>50%)下;在测量单维或二维肿瘤大小减少的研究中,出现了较低的灵敏度/特异性对。然而,研究方法和数据报告的局限性限制了明确的结论。解决这些局限性的方法包括:MRI 参数之间的统计比较,以及 MRI 与其他测试(特别是超声和临床检查)之间的比较;标准化 MRI 阈值和 pCR 定义;以及根据测试结果报告 NAC 的变化。有必要进行进一步采用这些方法的研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验